/LH
LH Stock - Labcorp Holdings Inc.
Healthcare|Medical - Equipment & ServicesNYSE
$252.03+0.00%
+$0.00 (+0.00%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.39
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+25.3%upside
Target: $315.79
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$249.51 – $254.55
TARGET (TP)$315.75
STOP LOSS$231.87
RISK/REWARD1:3.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.96
52W High$293.72
52W Low$209.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $13.01B | $12.16B | $11.86B | $13.14B | $13.98B |
| Gross Profit | $3.62B | $3.36B | $3.71B | $4.99B | $4.95B |
| Gross Margin | 27.9% | 27.7% | 31.3% | 38.0% | 35.4% |
| Operating Income | $1.09B | $725.60M | $1.44B | $3.05B | $2.45B |
| Net Income | $746.00M | $418.00M | $1.28B | $2.38B | $1.56B |
| Net Margin | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% |
| EPS | $8.89 | $4.80 | $14.04 | $24.58 | $15.99 |
Company Overview
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
54%
Hold / Neutral
6
46%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
7 Bullish6 Neutral/Bearish
Price Targets
$257
Average Target
↑ 2.0% Upside
Now
$210
Low
$257
Average
$300
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 10th 2025 | HSBC Securities | Downgrade | Hold | $260 |
| April 2nd 2025 | Redburn Atlantic | Initiation | Buy | $276 |
| March 4th 2025 | Citigroup | Upgrade | Buy | $300← $250 |
| January 7th 2025 | Evercore ISI | Upgrade | Outperform | $265← $260 |
| December 10th 2024 | Jefferies | Resumed | Buy | $275← $265 |
| October 30th 2024 | HSBC Securities | Upgrade | Buy | - |
| October 1st 2024 | Piper Sandler | Initiation | Neutral | $235 |
| March 25th 2024 | Argus | Upgrade | Buy | $250 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $260 |
| February 9th 2024 | Evercore ISI | Initiation | In-line | $240 |
| January 3rd 2024 | Barclays | Initiation | Equal Weight | $222 |
| September 6th 2023 | HSBC Securities | Initiation | Hold | $210 |
| December 12th 2022 | Citigroup | Downgrade | Neutral | $250← $275 |
| September 19th 2022 | Argus | Downgrade | Hold | - |
| August 22nd 2022 | Morgan Stanley | Resumed | Overweight | $300 |
Earnings History & Surprises
LHBeat Rate
89%
Last 18 quarters
Avg Surprise
+5.1%
EPS vs Estimate
Beats / Misses
16/2
Last 12 quarters
Latest EPS
$4.18
Q4 2025
EPS Surprise History
Q1 24
+0.3%
$3.30vs$3.29
Q2 24
+5.7%
$3.68vs$3.48
Q3 24
+4.2%
$3.94vs$3.78
Q4 24
+0.9%
$3.50vs$3.47
Q1 25
+1.8%
$3.45vs$3.39
Q2 25
+2.7%
$3.84vs$3.74
Q3 25
+4.3%
$4.35vs$4.17
Q4 25
+1.2%
$4.18vs$4.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $3.95 | — | — | — |
Q4 2025 | Oct 28, 2025 | $4.13 | $4.18 | +1.2% | ✓ BEAT |
Q3 2025 | Jul 24, 2025 | $4.17 | $4.35 | +4.3% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $3.74 | $3.84 | +2.7% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $3.39 | $3.45 | +1.8% | ✓ BEAT |
Q4 2024 | Oct 24, 2024 | $3.47 | $3.50 | +0.9% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $3.78 | $3.94 | +4.2% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $3.48 | $3.68 | +5.7% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $3.29 | $3.30 | +0.3% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $3.37 | $3.38 | +0.3% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $3.47 | $3.42 | -1.4% | ✗ MISS |
Q2 2023 | Apr 25, 2023 | $3.99 | $3.82 | -4.3% | ✗ MISS |
Q1 2023 | Feb 16, 2023 | $4.06 | $4.14 | +2.0% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $4.67 | $4.68 | +0.2% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $4.70 | $4.95 | +5.3% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $5.98 | $6.11 | +2.2% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $5.80 | $6.77 | +16.7% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $4.92 | $6.82 | +38.6% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $5.53 | $6.13 | +10.8% | ✓ BEAT |
Latest News
JP Morgan Maintains Overweight on Labcorp Hldgs, Raises Price Target to $317
📈 PositiveBenzinga•Nov 7, 2025, 07:55 PM
UBS Maintains Buy on Labcorp Hldgs, Lowers Price Target to $320
➖ NeutralBenzinga•Oct 29, 2025, 05:38 PM•Also:
Labcorp shares are trading lower after the company lowered its FY2025 sales guidance.
📉 NegativeBenzinga•Oct 28, 2025, 01:53 PM
Labcorp Hldgs Raises FY2025 Adj EPS Guidance from $16.05-$16.50 to $16.15-$16.50 vs $16.32 Est; Lowers FY2025 Sales Guidance from $14.080B-$14.230B to $13.973B-$14.051B vs $14.008B Est
➖ NeutralBenzinga•Oct 28, 2025, 10:53 AM
Laboratory Corp Q3 Adj. EPS $4.18 Beats $4.13 Estimate, Sales $3.564B Beat $3.559B Estimate
📈 PositiveBenzinga•Oct 28, 2025, 10:52 AM
Labcorp To Offer First FDA-Cleared Blood Test In Primary Care To Rule Out Alzheimer's-Related Amyloid Pathology; Nationwide Availability Of Roche's Elecsys pTau181 By Early 2026
📈 PositiveBenzinga•Oct 23, 2025, 11:11 AM•Also:
UBS Maintains Buy on Labcorp Hldgs, Raises Price Target to $325
📈 PositiveBenzinga•Oct 17, 2025, 01:55 PM
Mizuho Maintains Outperform on Labcorp Hldgs, Raises Price Target to $320
📈 PositiveBenzinga•Oct 17, 2025, 01:22 PM
Evercore ISI Group Maintains Outperform on Labcorp Hldgs, Raises Price Target to $305
📈 PositiveBenzinga•Oct 3, 2025, 04:09 PM
Labcorp Teams Up With Roche To Bring Digital Pathology Scanners To US Labs, Adopts New Digital Imaging Tech To Improve Cancer And Disease Diagnoses
📈 PositiveBenzinga•Sep 30, 2025, 11:07 AM•Also:
Labcorp Announced The Availability Of Lumipulse pTau-217/Beta Amyloid 42 Ratio, First Blood-Based In-vitro Diagnostic Test Cleared By FDA For Diagnosis Of Alzheimer's Disease
📈 PositiveBenzinga•Aug 18, 2025, 11:04 AM
Frequently Asked Questions about LH
What is LH's current stock price?
Labcorp Holdings Inc. (LH) is currently trading at $252.03 per share. The stock has moved +0.00% today.
What is the analyst price target for LH?
The average analyst price target for LH is $315.75, based on 1 analyst.
What sector is Labcorp Holdings Inc. in?
Labcorp Holdings Inc. operates in the Healthcare sector, specifically within the Medical - Equipment & Services industry. The company is traded on the NYSE exchange.
What is LH's market cap?
Labcorp Holdings Inc. has a market capitalization of $20.89 billion, making it a large-cap company.
Does LH pay dividends?
No, Labcorp Holdings Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIIB
Biogen Inc.
$174.80
Mkt Cap: $25.6B
DGX
Quest Diagnostics Incorporated
$176.06
Mkt Cap: $19.7B
DXCM
DexCom, Inc.
$66.06
Mkt Cap: $25.8B
ILMN
Illumina, Inc.
$134.78
Mkt Cap: $20.6B
INCY
Incyte Corporation
$102.69
Mkt Cap: $20.2B
STE
STERIS plc
$254.34
Mkt Cap: $25.0B
UTHR
United Therapeutics Corporation
$517.13
Mkt Cap: $23.1B
WAT
Waters Corporation
$378.03
Mkt Cap: $22.5B
WST
West Pharmaceutical Services, Inc.
$272.54
Mkt Cap: $19.6B
ZBH
Zimmer Biomet Holdings, Inc.
$89.13
Mkt Cap: $17.7B
Explore stocks similar to LH for comparison